Krystal Biotech (NASDAQ:KRYS) EVP Sells $347,270.00 in Stock

Posted by Geri Gentry on Jun 26th, 2026

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the sale, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Charles Thomas also recently made the following trade(s):

On Tuesday, May 26th, John Charles Thomas sold 642 shares of Krystal Biotech stock. The stock was sold at an average price of $302.03, for a total value of $193,903.26.

Krystal Biotech Stock Up 3.4%

Krystal Biotech stock traded up $12.32 during midday trading on Friday, reaching $372.25. 1,307,695 shares of the stock traded hands, compared to its average volume of 308,876. The stock has a market cap of $10.97 billion, a P/E ratio of 49.77 and a beta of 0.53. The stock’s fifty day moving average is $302.65 and its 200-day moving average is $276.02. Krystal Biotech, Inc. has a 12 month low of $130.50 and a 12 month high of $376.28.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The business had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, equities analysts predict that Krystal Biotech, Inc. will post 7.66 EPS for the current fiscal year.

Analyst Ratings Changes

KRYS has been the topic of a number of recent research reports. Citigroup upped their price target on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. Weiss Ratings upgraded shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research report on Tuesday, June 16th. Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Wolfe Research began coverage on Krystal Biotech in a research report on Friday, March 27th. They issued a “peer perform” rating for the company. Ten analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $340.56.

Read Our Latest Stock Report on Krystal Biotech

Institutional Trading of Krystal Biotech

Institutional investors have recently bought and sold shares of the stock. Western Wealth Management LLC purchased a new position in Krystal Biotech during the first quarter worth $34,000. Greenline Wealth Management LLC bought a new stake in shares of Krystal Biotech in the 4th quarter worth about $34,000. Sound Income Strategies LLC lifted its holdings in shares of Krystal Biotech by 1,270.0% in the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after acquiring an additional 127 shares during the last quarter. UMB Bank n.a. boosted its stake in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares during the period. Finally, Global Retirement Partners LLC boosted its stake in shares of Krystal Biotech by 788.9% during the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after purchasing an additional 142 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

(Get Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.